• Genesis Biopharma Inc., of Los Angeles, added Gray Davis as chairman of its corporate advisory board. It also named Patrick Hwu and Mario Sznol to its recently formed scientific and medical advisory board and named Martin Schroeder to its board.

• Heat Biologics, of Miami, appointed Sol J. Barer to its scientific and clinical advisory board.

• Histogen Inc., of San Diego, named David Nassif president and chief financial officer.

• Inhibikase Therapeutics Inc., of Atlanta, elected Steven C. Gilman to its board.

• IntelGenx Technologies Corp., of Saint Laurent, Quebec, added Rajiv Khosla to its board.

• Kinex Pharmaceuticals LLC, of Buffalo, N.Y., named David Hangauer chief scientific officer.

• Marshall Edwards Inc., of San Diego, appointed Robert Mass chief medical officer.

• Micromet Inc., of Rockville, Md., appointed Ulrich Grau executive vice president and chief operating officer.

• Mucosis BV, of Groningen, the Netherlands, appointed Thomas Johnston chief business officer.

• NanoBio Corp., of Ann Arbor, Mich., appointed George Arida to its board.

• Neovacs SA, of Paris, added Edmond Alphandery, Arlene Morris and Patrick Valroff to its board.

• Northwest Biotherapeutics Inc., of Bethesda, Md., named Linda Powers CEO. It also appointed Anthony Maida chief operating officer, effective June 20, and Alton Boynton chief scientific officer. Les Goldman was named senior vice president of business development.

• NovImmune SA, of Plan-Les-Ouates, Switzerland, nominated Klaus Strein to its board.

• NuPathe Inc., of Conshohocken, Pa., appointed Robert J. Murphy vice president of sales and David T. McGovern head of marketing.

• OctoPlus NV, of Leiden, the Netherlands, appointed Jan H. Egberts to the executive board.

• Olympus Biotech, of Hopkinton, Mass., appointed Oliver Burckhardt president.

• OncoSec Medical Inc., of San Diego, named Paul Goldfarb medical director and Ernest Kitt executive director of clinical operations.

• Oragenics Inc., of Tampa, Fla., named John N. Bonfiglio president, CEO and board member.

• Otonomy Inc., of San Diego, appointed Gerald Wroblewski chief operations officer.

• Oxford BioMedica plc, of Oxford, UK, appointed Alex Lewis director of corporate activities and strategy.